| Date | Time | Source | Headline | Symbol | Company |
| 11/22/2023 | 5:12PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 5:11PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 5:11PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 5:10PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 5:10PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 4:38PM | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 4:21PM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 4:12PM | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/22/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/20/2023 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/20/2023 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/20/2023 | 6:25AM | IH Market News | Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/16/2023 | 4:31PM | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 11/13/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/13/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 10/06/2023 | 2:34PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/17/2023 | 12:00PM | Business Wire | Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/07/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 09/01/2023 | 6:51PM | PR Newswire (US) | Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/31/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate in Investor Conferences in September | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/08/2023 | 4:23PM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/08/2023 | 4:01PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/07/2023 | 4:06PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 08/07/2023 | 4:01PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 07/31/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/20/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/07/2023 | 7:02AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 06/07/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/31/2023 | 7:00AM | Business Wire | Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 05/09/2023 | 5:08PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |